GENINCODE PLC LS -01 (9PL) - Net Assets
Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) has net assets worth €2.66 Million EUR (≈ $3.11 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.22 Million ≈ $4.93 Million USD) and total liabilities (€1.56 Million ≈ $1.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 9PL financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.66 Million |
| % of Total Assets | 63.09% |
| Annual Growth Rate | -56.52% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.16 |
GENINCODE PLC LS -01 - Net Assets Trend (2021–2024)
This chart illustrates how GENINCODE PLC LS -01's net assets have evolved over time, based on quarterly financial data. Also explore GENINCODE PLC LS -01 (9PL) total assets for the complete picture of this company's asset base.
Annual Net Assets for GENINCODE PLC LS -01 (2021–2024)
The table below shows the annual net assets of GENINCODE PLC LS -01 from 2021 to 2024. For live valuation and market cap data, see how much is GENINCODE PLC LS -01 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.13 Million ≈ $1.32 Million |
-12.57% |
| 2023-12-31 | €1.29 Million ≈ $1.51 Million |
-83.68% |
| 2022-12-31 | €7.90 Million ≈ $9.24 Million |
-42.41% |
| 2021-12-31 | €13.72 Million ≈ $16.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GENINCODE PLC LS -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1700900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €21.07 Million | 1869.74% |
| Total Equity | €1.13 Million | 100.00% |
GENINCODE PLC LS -01 Competitors by Market Cap
The table below lists competitors of GENINCODE PLC LS -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Media Lab SpA
PA:MLLAB
|
$8.48 Million |
|
NORDIC TECH.GRP.NK-00423
F:UA5
|
$8.49 Million |
|
Aurora Energy Metals Ltd
AU:1AE
|
$8.49 Million |
|
Alliance Developpement Capital SIIC SE
PA:ALDV
|
$8.49 Million |
|
National Plastic Co Ltd Preferred
KO:004255
|
$8.48 Million |
|
Ace Digital AS
OL:ACED
|
$8.48 Million |
|
Spago Nanomedical AB
ST:SPAGO
|
$8.47 Million |
|
Truscreen Group Ltd
AU:TRU
|
$8.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENINCODE PLC LS -01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,289,000 to 1,127,000, a change of -162,000 (-12.6%).
- Net loss of 4,434,000 reduced equity.
- New share issuances of 3,743,000 increased equity.
- Other factors increased equity by 529,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.43 Million | -393.43% |
| Share Issuances | €3.74 Million | +332.12% |
| Other Changes | €529.00K | +46.94% |
| Total Change | €- | -12.57% |
Book Value vs Market Value Analysis
This analysis compares GENINCODE PLC LS -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.07x to 1.57x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.14 | €0.01 | x |
| 2022-12-31 | €0.08 | €0.01 | x |
| 2023-12-31 | €0.01 | €0.01 | x |
| 2024-12-31 | €0.01 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GENINCODE PLC LS -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -393.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -164.16%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 2.36x
- Recent ROE (-393.43%) is below the historical average (-259.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -30.19% | -358.93% | 0.08x | 1.11x | €-5.51 Million |
| 2022 | -70.37% | -388.74% | 0.12x | 1.49x | €-6.35 Million |
| 2023 | -544.30% | -324.81% | 0.52x | 3.25x | €-7.14 Million |
| 2024 | -393.43% | -164.16% | 1.01x | 2.36x | €-4.55 Million |
Industry Comparison
This section compares GENINCODE PLC LS -01's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,070,781,530
- Average return on equity (ROE) among peers: -141.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENINCODE PLC LS -01 (9PL) | €2.66 Million | -30.19% | 0.59x | $8.48 Million |
| IZOTROPIC CORP. (1R3) | $-3.85 Million | 0.00% | 0.00x | $9.91 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $637.00K | -555.57% | 21.06x | $1.47 Million |
| Check-Cap Ltd (7CC) | $6.23 Million | -221.94% | 0.51x | $9.91 Million |
| INOVIQ LTD. (EGQ0) | $19.62 Million | -45.73% | 0.10x | $29.30 Million |
| Eurofins Scientific SE (ESF0) | $5.14 Billion | 6.04% | 1.12x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $9.24 Billion | 6.63% | 0.84x | $8.69 Billion |
| NanoRepro AG (NN6) | $238.29K | -330.81% | 0.82x | $18.79 Million |
| WuXi AppTec Co. Ltd (WX8) | $18.17 Billion | 12.44% | 0.25x | $8.77 Billion |
About GENINCODE PLC LS -01
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to prov… Read more